



US008058068B2

(12) **United States Patent**  
**Hawley-Nelson et al.**

(10) **Patent No.:** **US 8,058,068 B2**  
(45) **Date of Patent:** **\*Nov. 15, 2011**

(54) **PEPTIDE-ENHANCED TRANSFECTIONS**

(75) Inventors: **Pamela Hawley-Nelson**, Silver Spring, MD (US); **Jianqing Lan**, Germantown, MD (US); **PoJen Shih**, Columbia, MD (US); **Joel A. Jessee**, Mt. Airy, MD (US); **Kevin P. Schifferli**, Germantown, MD (US); **Gullilat Gebeyehu**, Silver Springs, MD (US); **Valentina C. Ciccarone**, Gaithersburg, MD (US); **Krista L. Evans**, Germantown, MD (US)

(73) Assignee: **Life Technologies Corporation**, Carlsbad, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 315 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/200,879**

(22) Filed: **Jul. 23, 2002**

(65) **Prior Publication Data**

US 2003/0144230 A1 Jul. 31, 2003

**Related U.S. Application Data**

(63) Continuation of application No. 09/911,569, filed on Jul. 23, 2001, now abandoned, which is a continuation of application No. 09/039,780, filed on Mar. 16, 1998, now Pat. No. 6,376,248, which is a continuation-in-part of application No. 08/818,200, filed on Mar. 14, 1997, now Pat. No. 6,051,429, which is a continuation-in-part of application No. 08/658,130, filed on Jun. 4, 1996, now Pat. No. 5,736,392, which is a continuation-in-part of application No. 08/477,354, filed on Jun. 7, 1995, now abandoned.

(51) **Int. Cl.**

**C12N 15/88** (2006.01)  
**C07K 14/00** (2006.01)  
**C07K 14/025** (2006.01)  
**C07H 21/02** (2006.01)  
**C07H 21/04** (2006.01)

(52) **U.S. Cl.** ..... **435/458; 530/324; 428/402.2; 536/23.1**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,235,871 A 11/1980 Papahadjopoulos  
4,897,355 A 1/1990 Eppstein et al.  
4,946,787 A 8/1990 Eppstein et al.  
4,959,217 A 9/1990 Sanders et al.  
5,165,925 A 11/1992 Leong  
5,166,320 A 11/1992 Wu et al.  
5,196,510 A 3/1993 Rodwell et al.  
5,198,423 A 3/1993 Taguchi et al.

5,264,618 A 11/1993 Felgner et al.  
5,266,106 A 11/1993 Breton  
5,279,833 A 1/1994 Rose  
5,283,185 A 2/1994 Epand et al.  
5,328,984 A 7/1994 Pastan et al.  
5,334,761 A 8/1994 Gebeyehu et al.  
5,338,532 A 8/1994 Tomalia et al.  
5,342,921 A 8/1994 Cousens et al.  
5,354,844 A 10/1994 Beug et al.  
5,491,074 A 2/1996 Aldwin et al.  
5,521,291 A 5/1996 Curiel et al.  
5,527,524 A 6/1996 Tomalia et al.  
5,532,142 A 7/1996 Johnston et al.  
5,545,412 A 8/1996 Eppstein et al.  
5,547,932 A 8/1996 Curiel et al.  
5,560,929 A 10/1996 Hedstrand et al.  
5,574,142 A 11/1996 Meyer, Jr. et al.  
5,578,475 A 11/1996 Jessee  
5,583,198 A 12/1996 Whittaker  
5,587,441 A 12/1996 Frechet et al.  
5,587,446 A 12/1996 Frechet et al.  
5,589,392 A 12/1996 Short  
5,589,466 A 12/1996 Felgner et al.  
5,595,897 A 1/1997 Midoux et al.  
5,595,899 A 1/1997 Sato et al.  
5,627,159 A 5/1997 Shih et al.  
5,631,329 A 5/1997 Yin et al.  
5,650,096 A 7/1997 Harris et al.  
5,658,776 A 8/1997 Flotte et al.  
5,661,025 A 8/1997 Szoka, Jr. et al.  
5,670,347 A 9/1997 Gopal

(Continued)

FOREIGN PATENT DOCUMENTS

AU B-26526/92 9/1992

(Continued)

OTHER PUBLICATIONS

Verma et al. Gene Therapy—promises, problems and prospects. Nature. vol. 389, No. 6648, pp. 239-242, Sep. 1997.\* Palu et al. In pursuit of new developments for gene therapy of human diseases. J Biotechnol. vol. 68, No. 1, pp. 1-13, Feb. 1999.\* Luo et al. Synthetic DNA delivery systems. Nat Biotechnol. vol. 18, No. 1, pp. 33-37, Jan. 2000.\* Edelstein et al. Gene therapy clinical trials worldwide 1989-2004— an overview. J Gene Med. vol. 6, No. 6:597-602, Jun. 2004.\* Remy et al. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses. PNAS, USA. vol. 92, No. 5, pp. 1744-1748, Feb. 28, 1995.\*

(Continued)

Primary Examiner — Jennifer Dunston

(57) **ABSTRACT**

The present invention provides compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

**25 Claims, 16 Drawing Sheets**